JPH1160432A - Skin cosmetic - Google Patents
Skin cosmeticInfo
- Publication number
- JPH1160432A JPH1160432A JP21752897A JP21752897A JPH1160432A JP H1160432 A JPH1160432 A JP H1160432A JP 21752897 A JP21752897 A JP 21752897A JP 21752897 A JP21752897 A JP 21752897A JP H1160432 A JPH1160432 A JP H1160432A
- Authority
- JP
- Japan
- Prior art keywords
- skin
- cosmetic
- fatty acid
- agent
- cholesterol ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract description 25
- 239000000194 fatty acid Substances 0.000 claims abstract description 42
- 235000014113 dietary fatty acids Nutrition 0.000 claims abstract description 37
- 229930195729 fatty acid Natural products 0.000 claims abstract description 37
- 150000004665 fatty acids Chemical class 0.000 claims abstract description 16
- 150000003408 sphingolipids Chemical class 0.000 claims abstract description 16
- 150000001840 cholesterol esters Chemical class 0.000 claims abstract description 13
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 claims abstract description 10
- 239000004202 carbamide Substances 0.000 claims abstract description 10
- 150000001875 compounds Chemical class 0.000 claims abstract description 3
- 239000003795 chemical substances by application Substances 0.000 abstract description 5
- 239000000049 pigment Substances 0.000 abstract description 3
- 150000001413 amino acids Chemical class 0.000 abstract description 2
- 239000003963 antioxidant agent Substances 0.000 abstract description 2
- 238000003287 bathing Methods 0.000 abstract description 2
- 239000002738 chelating agent Substances 0.000 abstract description 2
- 239000006071 cream Substances 0.000 abstract description 2
- 239000006210 lotion Substances 0.000 abstract description 2
- 239000003921 oil Substances 0.000 abstract description 2
- 239000003755 preservative agent Substances 0.000 abstract description 2
- 150000003839 salts Chemical class 0.000 abstract description 2
- 150000005846 sugar alcohols Polymers 0.000 abstract description 2
- 239000004094 surface-active agent Substances 0.000 abstract description 2
- 239000011782 vitamin Substances 0.000 abstract description 2
- 229940088594 vitamin Drugs 0.000 abstract description 2
- 229930003231 vitamin Natural products 0.000 abstract description 2
- 235000013343 vitamin Nutrition 0.000 abstract description 2
- 206010040849 Skin fissures Diseases 0.000 abstract 1
- 238000010521 absorption reaction Methods 0.000 abstract 1
- 230000003078 antioxidant effect Effects 0.000 abstract 1
- 150000001720 carbohydrates Chemical class 0.000 abstract 1
- 238000004040 coloring Methods 0.000 abstract 1
- 229920000642 polymer Polymers 0.000 abstract 1
- 230000002335 preservative effect Effects 0.000 abstract 1
- 210000003491 skin Anatomy 0.000 description 52
- -1 fatty acid cholesterol ester Chemical class 0.000 description 23
- 238000012360 testing method Methods 0.000 description 21
- 230000000694 effects Effects 0.000 description 18
- 239000000306 component Substances 0.000 description 17
- 239000000203 mixture Substances 0.000 description 15
- 230000006870 function Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 10
- 230000000052 comparative effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 230000009467 reduction Effects 0.000 description 8
- 239000002884 skin cream Substances 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- 102000001708 Protein Isoforms Human genes 0.000 description 6
- 108010029485 Protein Isoforms Proteins 0.000 description 6
- 230000014759 maintenance of location Effects 0.000 description 6
- 125000004432 carbon atom Chemical group C* 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 239000000686 essence Substances 0.000 description 5
- 239000004973 liquid crystal related substance Substances 0.000 description 5
- 230000003020 moisturizing effect Effects 0.000 description 5
- 238000002360 preparation method Methods 0.000 description 5
- XDOFQFKRPWOURC-UHFFFAOYSA-N 16-methylheptadecanoic acid Chemical compound CC(C)CCCCCCCCCCCCCCC(O)=O XDOFQFKRPWOURC-UHFFFAOYSA-N 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 238000010998 test method Methods 0.000 description 4
- MYWSBJKVOUZCIA-UHFFFAOYSA-N 2-hydroxy-3,5-diiodobenzaldehyde Chemical compound OC1=C(I)C=C(I)C=C1C=O MYWSBJKVOUZCIA-UHFFFAOYSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- YDNKGFDKKRUKPY-JHOUSYSJSA-N C16 ceramide Natural products CCCCCCCCCCCCCCCC(=O)N[C@@H](CO)[C@H](O)C=CCCCCCCCCCCCCC YDNKGFDKKRUKPY-JHOUSYSJSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- CRJGESKKUOMBCT-VQTJNVASSA-N N-acetylsphinganine Chemical compound CCCCCCCCCCCCCCC[C@@H](O)[C@H](CO)NC(C)=O CRJGESKKUOMBCT-VQTJNVASSA-N 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 239000013040 bath agent Substances 0.000 description 3
- 239000003788 bath preparation Substances 0.000 description 3
- 229940106189 ceramide Drugs 0.000 description 3
- ZVEQCJWYRWKARO-UHFFFAOYSA-N ceramide Natural products CCCCCCCCCCCCCCC(O)C(=O)NC(CO)C(O)C=CCCC=C(C)CCCCCCCCC ZVEQCJWYRWKARO-UHFFFAOYSA-N 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 238000012937 correction Methods 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- VVGIYYKRAMHVLU-UHFFFAOYSA-N newbouldiamide Natural products CCCCCCCCCCCCCCCCCCCC(O)C(O)C(O)C(CO)NC(=O)CCCCCCCCCCCCCCCCC VVGIYYKRAMHVLU-UHFFFAOYSA-N 0.000 description 3
- SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 206010013786 Dry skin Diseases 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 230000037336 dry skin Effects 0.000 description 2
- 210000002615 epidermis Anatomy 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 210000002510 keratinocyte Anatomy 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 230000009993 protective function Effects 0.000 description 2
- 238000010898 silica gel chromatography Methods 0.000 description 2
- 230000036620 skin dryness Effects 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000005068 transpiration Effects 0.000 description 2
- YLZIMEJTDZWVJG-UHFFFAOYSA-N 2-heptylundecanoic acid Chemical compound CCCCCCCCCC(C(O)=O)CCCCCCC YLZIMEJTDZWVJG-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 101150009575 RH10 gene Proteins 0.000 description 1
- 239000006096 absorbing agent Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- WPIHMWBQRSAMDE-YCZTVTEBSA-N beta-D-galactosyl-(1->4)-beta-D-galactosyl-N-(pentacosanoyl)sphingosine Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCC(=O)N[C@@H](CO[C@@H]1O[C@H](CO)[C@H](O[C@@H]2O[C@H](CO)[C@H](O)[C@H](O)[C@H]2O)[C@H](O)[C@H]1O)[C@H](O)\C=C\CCCCCCCCCCCCC WPIHMWBQRSAMDE-YCZTVTEBSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 238000010835 comparative analysis Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000000245 forearm Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000002270 gangliosides Chemical class 0.000 description 1
- 238000004817 gas chromatography Methods 0.000 description 1
- 150000002305 glucosylceramides Chemical class 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- DDOVBCWVTOHGCU-QMXMISKISA-N n-[(e,2s,3r)-3-hydroxy-1-[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxynonadec-4-en-2-yl]octadecanamide Chemical compound CCCCCCCCCCCCCCCCCC(=O)N[C@H]([C@H](O)\C=C\CCCCCCCCCCCCCC)CO[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O DDOVBCWVTOHGCU-QMXMISKISA-N 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
Landscapes
- Cosmetics (AREA)
Abstract
Description
【0001】[0001]
【発明の属する技術分野】本発明は、医薬部外品、化粧
品等に適用される皮膚化粧料に関し、更に詳しくは、皮
膚の水分保持機能を持続的に亢進、維持することによ
り、荒れ肌改善効果を持ち、使用感にも優れた新規皮膚
化粧料に関する。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a skin cosmetic applied to quasi-drugs, cosmetics and the like, and more particularly, to an effect of improving rough skin by continuously enhancing and maintaining the moisture retention function of the skin. And a novel skin cosmetic having excellent usability.
【0002】[0002]
【従来の技術】皮膚の水分は、真皮の基底細胞層から表
皮の角質層へと外層に向かうにつれて減少する水分含量
の勾配に沿って、常に皮膚内部から外層部へ移動し、角
質層を通じて外部へ蒸散している。この水分蒸散は主に
角質層の緻密な細胞組織からなる防御機能(バリヤー機
能)により制御されており、該水分蒸散量(Trans
epidermal Water Loss、以下TW
Lと略す)は、例えば健常な皮膚の正常な状態における
ヒトの前腕部皮表では0.2〜0.3mg/cm2/hrの範
囲、通常は0.25mg/cm2/hr 程度以下に保持されてい
る。これに対して、老化皮膚や乾燥皮膚等にみられる荒
れ肌では、その程度に応じてTWL値は上記の範囲の上
限値もしくはそれより大きな値を示し、皮膚の水分保持
機能が低下していることが認められる。これらの荒れ肌
の場合、角質層の防御機能による通常の制御限界を超え
た状態にあるか、あるいは該防御機能が衰えていること
に由来するものである。2. Description of the Related Art Moisture of the skin always moves from the inside of the skin to the outer layer along a gradient of water content that decreases from the basal cell layer of the dermis to the stratum corneum of the epidermis and toward the outer layer. Has transpired. This water transpiration is controlled mainly by a defense function (barrier function) composed of a dense cell tissue in the stratum corneum, and the water transpiration (Trans)
epidermal Water Loss, TW
Abbreviated as L), for example healthy range 0.2~0.3mg / cm 2 / hr in the forearm skin surface of the person in the normal condition of the skin, usually below about 0.25mg / cm 2 / hr Is held. On the other hand, in the case of rough skin such as aging skin and dry skin, the TWL value shows the upper limit of the above range or a value larger than that depending on the degree, and the moisture retention function of the skin is reduced. Is recognized. In the case of these rough skins, it is due to a state where the normal control limit by the protective function of the stratum corneum has been exceeded or the protective function has deteriorated.
【0003】従来より、皮膚老化の要因である水分保持
機能の低下を防ぐことを期待して、スフィンゴ脂質、脂
肪酸、コレステロール及びコレステロールエステル等、
角質層に本来存在し、水分保持機能を担っている脂質成
分を皮膚に適用する方法が提案されている(特公平4−
57641号公報、特開昭61−260008号公報、
特開昭62−29508号公報)。これらの脂質成分は
皮膚に適用した際、皮膚上で水を含んだ液晶状態を形成
し、皮膚からの水分蒸散を防止するとともに、保水性を
向上させ、皮膚機能を正常に維持するものである。[0003] Conventionally, sphingolipids, fatty acids, cholesterol, cholesterol esters, and the like have been used in anticipation of preventing a decrease in water retention function which is a factor of skin aging.
A method has been proposed in which a lipid component that is originally present in the stratum corneum and has a water retention function is applied to the skin (Japanese Patent Publication No. Hei 4-
No. 57641, JP-A-61-260008,
JP-A-62-29508). These lipid components, when applied to the skin, form a water-containing liquid crystal state on the skin, prevent water evaporation from the skin, improve water retention, and maintain normal skin function. .
【0004】しかしながら、これらの脂質成分を適用し
たところで、一時的には皮膚を健常な状態に保持するこ
とはできても、持続性は乏しく、荒れ肌を修繕するには
至らなかった。[0004] However, when these lipid components are applied, the skin can be temporarily kept in a healthy state, but the persistence is poor, and the rough skin cannot be repaired.
【0005】そこで本発明者らは、水分保持機能の亢進
を目的として、イソ型脂肪酸及び/又はアンテイソ型脂
肪酸のコレステロールエステル、ならびにスフィンゴ脂
質類より選ばれる少なくとも一種を必須成分とすること
を特徴とする皮膚化粧料を提案している(特開平9−1
24456号公報)。しかしながら、水分保持機能亢進
効果は認められるものの、荒れ肌改善効果は必ずしも充
分でない。[0005] Therefore, the present inventors characterized in that at least one selected from cholesterol esters of iso-type fatty acids and / or anteiso-type fatty acids and sphingolipids is an essential component for the purpose of enhancing the water retention function. (Japanese Patent Laid-Open No. 9-1)
No. 24456). However, although the effect of enhancing the water retention function is recognized, the effect of improving rough skin is not always sufficient.
【0006】一方、尿素は、皮膚の水分保持機能に非常
に重要であるとされる天然保湿因子(NMF)成分の一
つであり、角質の水分保持力を高めるとともに角質溶解
作用、抗菌作用があるといわれ、荒れ肌防止や保湿機能
などを期待して、従来から医薬部外品や化粧品に広く用
いられている。しかしながら、尿素単独あるいは尿素を
配合した従来の製剤では必ずしも充分な水分保持能は得
られず、持続的な荒れ肌改善効果は得られていない。[0006] On the other hand, urea is one of the natural moisturizing factors (NMF) components, which are considered to be very important for the moisture retention function of the skin. It has been widely used in quasi-drugs and cosmetics in anticipation of preventing rough skin and moisturizing function. However, conventional formulations containing urea alone or urea do not always provide sufficient moisture retention, and do not provide a sustained effect on improving rough skin.
【0007】[0007]
【発明が解決しようとする課題】本発明は、皮膚の水分
保持機能を持続的に亢進、維持することにより、荒れ肌
の改善効果を持ち、使用感にも優れた新規皮膚化粧料を
提供することを目的とする。DISCLOSURE OF THE INVENTION The present invention provides a novel skin cosmetic which has an effect of improving rough skin and has excellent usability by continuously enhancing and maintaining the moisture retention function of the skin. With the goal.
【0008】[0008]
【課題を解決するための手段】本発明者らは、上記の目
的を解決するため検討した結果、下記一般式(1)で表
されるイソ型脂肪酸のコレステロールエステル及び/又
は下記一般式(2)で表されるアンテイソ型脂肪酸のコ
レステロールエステル、並びに尿素を必須成分とする皮
膚化粧料が、その相乗効果により本目的を達成すること
を見いだした。Means for Solving the Problems The present inventors have studied to solve the above-mentioned object, and as a result, have found that cholesterol esters of iso-type fatty acids represented by the following general formula (1) and / or the following general formula (2) It has been found that cholesterol esters of anteiso-type fatty acids represented by formula (1) and skin cosmetics containing urea as essential components achieve this object by their synergistic effect.
【0009】[0009]
【化3】 Embedded image
【0010】(但し、nは6〜32で示される。)(However, n is represented by 6 to 32.)
【0011】[0011]
【化4】 Embedded image
【0012】(但し、nは6〜32で示される。)(Where n is 6 to 32)
【0013】更に、上記構成に、更にスフィンゴ脂質類
より選ばれる少なくとも一種を加えると、スフィンゴ脂
質類が容易に液晶構造を形成し、形成した液晶構造のた
め水分蒸散を抑制する効果が一段と増し、本目的に対し
格段に優れた効果を発現することを見いだした。すなわ
ち、本発明は、上記一般式(1)で表されるイソ型脂肪
酸のコレステロールエステル及び/又は上記一般式
(2)で表されるアンテイソ型脂肪酸のコレステロール
エステル、並びに尿素を必須成分として含有する皮膚化
粧料にある。また、本発明は、上記構成に、更にスフィ
ンゴ脂質類より選ばれる少なくとも一種を含有する皮膚
化粧料にある。Further, when at least one selected from sphingolipids is further added to the above-mentioned constitution, the sphingolipids easily form a liquid crystal structure, and the effect of suppressing water evaporation due to the formed liquid crystal structure is further increased. It has been found that a significantly superior effect is exhibited for this purpose. That is, the present invention contains, as essential components, a cholesterol ester of an iso-fatty acid represented by the general formula (1) and / or a cholesterol ester of an ante-iso-fatty acid represented by the general formula (2), and urea. In skin cosmetics. Further, the present invention is a skin cosmetic comprising at least one selected from sphingolipids in addition to the above constitution.
【0014】[0014]
【発明の実施の形態】以下、本発明の実施の形態を詳述
する。Embodiments of the present invention will be described below in detail.
【0015】従来より化粧品原料として用いられている
分岐脂肪酸コレステロールエステルは、イソステアリン
酸によって構成される。このイソステアリン酸は、分岐
位置および分岐アルキル鎖長は特定されていないが、ほ
とんどは2−ヘプチルウンデカン酸である。一方、本発
明で開示する分岐脂肪酸コレステロールエステルは、イ
ソ型、アンテイソ型脂肪酸によって構成される。すなわ
ち、それぞれ末端より2位〔前記一般式(1)〕、及び
末端より3位〔前記一般式(2)〕にメチル基を有する
脂肪酸に限定される。分岐位置および分岐アルキル鎖長
が特定されている点で本発明の分岐脂肪酸コレステロー
ルエステルは、従来公知化合物の分岐脂肪酸コレステロ
ールエステルとは異なる。The branched fatty acid cholesterol ester conventionally used as a raw material for cosmetics is composed of isostearic acid. This isostearic acid is mostly 2-heptylundecanoic acid, although the branch position and the branched alkyl chain length are not specified. On the other hand, the branched fatty acid cholesterol ester disclosed in the present invention is composed of iso-type and anteiso-type fatty acids. That is, it is limited to fatty acids having a methyl group at the 2-position from the terminal [the above-mentioned general formula (1)] and the 3-position from the terminal [the above-mentioned general formula (2)]. The branched fatty acid cholesterol ester of the present invention differs from the conventionally known branched fatty acid cholesterol ester in that the branch position and the branched alkyl chain length are specified.
【0016】本発明に用いる、分岐脂肪酸コレステロー
ルエステルはイソ型、アンテイソ型に分離する必要はな
いが、分離して用いても良い。また、これらの分岐脂肪
酸コレステロールエステルは他の脂肪酸コレステロール
エステルとの混合物で良いが、分岐脂肪酸コレステロー
ルエステルのみからなるものでも良い。これらのイソ型
脂肪酸及びアンテイソ型脂肪酸の総炭素数は融点が低
く、液晶構造を形成する範囲である、6〜32であり、
好ましくは総炭素数12〜28である。The branched fatty acid cholesterol ester used in the present invention does not need to be separated into an iso form and an ante iso form, but may be used separately. In addition, these branched fatty acid cholesterol esters may be a mixture with other fatty acid cholesterol esters, or may be composed of only branched fatty acid cholesterol esters. The total carbon number of these iso-type fatty acids and anteiso-type fatty acids has a low melting point and is in a range of forming a liquid crystal structure, that is, 6 to 32,
Preferably, the total number of carbon atoms is 12 to 28.
【0017】本発明で用いる、イソ型脂肪酸及び/又は
アンテイソ型脂肪酸のコレステロールエステルを含むこ
とを特徴とする脂肪酸コレステロールエステル混合物
は、ヒトなどの哺乳類の胎児表皮に存在するものであ
り、これら胎脂から得たものを用いることができる。ま
た、ラノリン中にも同様の構造の脂肪酸あるいはそのコ
レステロールエステルが存在することが知られており、
これに由来するものを用いることもできる。更には、こ
れらの構造のものは15−メチルヘプタデカン酸(イソ
型)をエステル化することによっても得ることができ、
これら合成品を用いることもできる。The fatty acid cholesterol ester mixture used in the present invention, which is characterized by containing a cholesterol ester of an iso-fatty acid and / or an anteiso-fatty acid, is present in the fetal epidermis of mammals such as humans. Can be used. It is also known that lanolin has a fatty acid or a cholesterol ester of a similar structure,
Those derived from this can also be used. Furthermore, those having these structures can also be obtained by esterifying 15-methylheptadecanoic acid (isoform),
These synthetic products can also be used.
【0018】本発明のイソ型脂肪酸及び/又はアンテイ
ソ型脂肪酸のコレステロールエステルの配合量は、最終
製剤の総量を基準として、大略0.01〜50重量%
(以下、wt%と略す)が好ましい。The amount of the cholesterol ester of the iso- and / or ante-iso fatty acids of the present invention is about 0.01 to 50% by weight, based on the total amount of the final preparation.
(Hereinafter abbreviated as wt%).
【0019】本発明で用いる、尿素は、公知の化合物
で、保湿剤としての用途の他に、殺菌剤、細胞賦活剤と
しても利用されている。Urea used in the present invention is a known compound, which is used not only as a humectant but also as a bactericide and a cell activator.
【0020】また、尿素の配合量は、最終製剤を基準と
して、大略0.01〜20wt%が好ましい。The amount of urea is preferably about 0.01 to 20% by weight based on the final preparation.
【0021】本発明で用いる、スフィンゴ脂質は、セラ
ミドの他、グルコシルセラミド、ガラクトシルセラミ
ド、ラクトシルセラミド、ガングリオシド等のスフィン
ゴ糖脂質、スフィンゴミエリン、セラミドホスホエタノ
ールアミン、セラミドホスホリルグリセロール等のスフ
ィンゴリン脂質などを挙げることができる。これらのス
フィンゴ脂質は、動植物からの抽出あるいは合成によっ
て得られるが、入手方法はこれに限定するものではな
い。The sphingolipids used in the present invention include, in addition to ceramide, sphingolipids such as glucosylceramide, galactosylceramide, lactosylceramide and ganglioside; sphingolipids such as sphingomyelin, ceramide phosphoethanolamine and ceramide phosphorylglycerol. Can be mentioned. These sphingolipids can be obtained by extraction or synthesis from plants and animals, but the method of obtaining them is not limited thereto.
【0022】また、スフィンゴ脂質の配合量は、最終製
剤を基準として、大略0.01〜30wt%が好まし
い。The amount of the sphingolipid is preferably about 0.01 to 30% by weight based on the final preparation.
【0023】本発明の皮膚化粧料には、必須成分の他に
必要に応じて油脂、色素、香料、防腐剤、界面活性剤、
顔料、酸化防止剤、キレート剤、紫外線吸収剤、紫外線
散乱剤、高分子系粘剤、糖類、塩類、多価アルコール、
ビタミン類、アミノ酸類等を本発明の目的を達成する範
囲内で適量配合し得る。In the skin cosmetic of the present invention, in addition to the essential components, fats and oils, pigments, fragrances, preservatives, surfactants,
Pigments, antioxidants, chelating agents, ultraviolet absorbers, ultraviolet scattering agents, polymeric adhesives, sugars, salts, polyhydric alcohols,
Appropriate amounts of vitamins, amino acids, and the like can be added as long as the object of the present invention is achieved.
【0024】本発明は中身性状により特に限定されるも
のではなく、水系、非水系の、メイクアップ化粧料ある
いは基礎化粧料に応用できる。例えば、メイクアップ化
粧料としては、ファンデーション類、口紅類等が挙げら
れる。また、基礎化粧料としては、クリーム類、乳液
類、ローション類、パック類、浴用剤等が挙げられる。The present invention is not particularly limited by the nature of the contents, and can be applied to aqueous or non-aqueous makeup cosmetics or basic cosmetics. For example, the makeup cosmetics include foundations, lipsticks and the like. Examples of the basic cosmetics include creams, emulsions, lotions, packs, bath agents and the like.
【0025】[0025]
【実施例】以下、実施例及び比較例を挙げて本発明を詳
説する。The present invention will be described in detail below with reference to examples and comparative examples.
【0026】本発明に係わる脂肪酸コレステロールエス
テル混合物の抽出法(ヒト胎脂由来、ラノリン由
来、合成法)は以下の通りである。The method for extracting the fatty acid cholesterol ester mixture (derived from human vernix, derived from lanolin, synthetic method) according to the present invention is as follows.
【0027】ヒト胎脂由来 出産直後の新生児の皮表より、脱脂綿を用いて胎脂をぬ
ぐい取り、この脱脂綿からクロロホルム/メタノール
(2:1)にて胎脂を抽出した。得られた胎脂からヘキ
サン及びベンゼンを展開溶媒としたシリカゲルカラムク
ロマトグラフィーによって、脂肪酸コレステロールエス
テル画分を得た。ガスクロマトグラフィーによって、こ
の画分には炭素数14〜26のイソ型脂肪酸コレステロ
ールエステルが約40%、炭素数15〜25のアンテイ
ソ型脂肪酸コレステロールエステルが約20%含まれて
いることを確認した。残部は不飽和脂肪酸コレステロー
ルエステルであった。これらの混合物を以下の実施例に
供した。Derived from human vernix The vernix was wiped off from the skin surface of a newborn baby immediately after childbirth using absorbent cotton, and vernix was extracted from the absorbent cotton with chloroform / methanol (2: 1). A fatty acid cholesterol ester fraction was obtained from the obtained vernix by silica gel column chromatography using hexane and benzene as a developing solvent. By gas chromatography, it was confirmed that this fraction contained about 40% of C14-26 isoform fatty acid cholesterol ester and about 20% of C15-C25 anteiso fatty acid cholesterol ester. The balance was unsaturated fatty acid cholesterol ester. These mixtures were subjected to the following examples.
【0028】ラノリン由来 本発明には、日本精化(株)製のYOFCO CLE−
NHを用いたが、これに限定されるものではない。YO
FCO CLE−NHは、羊毛脂を鹸化分解して得られ
るラノリン脂肪酸を公知の方法でコレステロールとエス
テル化して得られたものである。また、その組成は炭素
数12〜30のイソ型脂肪酸コレステロールエステルが
約35%、炭素数11〜31のアンテイソ型脂肪酸コレ
ステロールエステルが約40%含まれており、残部は炭
素数12〜30の直鎖脂肪酸コレステロールエステルで
ある。Lanolin Derivative The present invention includes YOFCO CLE- manufactured by Nippon Seika Co., Ltd.
Although NH was used, it is not limited to this. YO
FCO CLE-NH is obtained by esterifying lanolin fatty acid obtained by saponifying wool fat with cholesterol by a known method. The composition contains about 35% of an iso-type fatty acid cholesterol ester having 12 to 30 carbon atoms and about 40% of an ante-iso-type fatty acid cholesterol ester having 11 to 31 carbon atoms, and the balance is a straight-chain type having 12 to 30 carbon atoms. It is a chain fatty acid cholesterol ester.
【0029】合成品 市販の15−メチルヘプタデカン酸(アンテイソ型)を
従来公知の方法、すなわち、p−トルエンスルホン酸な
どの鉱酸を触媒として用い、減圧下で反応を行い、シリ
カゲルカラムクロマトグラフィーなどにより精製を行
い、15−メチルヘプタデカン酸コレステロールエステ
ルを得た。これらを以下の実施例に供した。Synthetic product Commercially available 15-methylheptadecanoic acid (anteiso type) is reacted under a reduced pressure using a conventionally known method, that is, using a mineral acid such as p-toluenesulfonic acid as a catalyst, and subjected to silica gel column chromatography. Purification was performed by, for example, obtaining cholesterol ester of 15-methylheptadecanoic acid. These were subjected to the following examples.
【0030】また、本発明に使用した(1)荒れ肌改善
効果試験法、(2)角質層改善効果試験法、(3)保湿
効果試験法(TWL値低減率)、(4)実用テスト(使
用感)は下記の通りである。Further, (1) rough skin improving effect test method, (2) stratum corneum improving effect test method, (3) moisturizing effect test method (TWL value reduction rate), (4) practical test (use) used in the present invention. Feeling) is as follows.
【0031】(1)荒れ肌改善効果試験法 下脚に、荒れ肌、乾燥肌などを訴える中高年女子被験者
(35〜55才)20名を対象として、4週間連続塗布
した効果を調べた。被験者の左側下脚試験部位に1日1
回約1gの試料を5×10cm面に塗布し、塗布開始前
及び塗布終了3日後の皮膚の状態を表1の皮膚乾燥度の
判定基準により肉眼判定した。なお、右側下脚は試料を
塗布せず対照とした。(1) Test Method for Improving Rough Skin Effectiveness The effect of continuous application for 4 weeks was examined on 20 middle-aged and elderly female subjects (35 to 55 years old) who complain of rough skin, dry skin, etc. on the lower leg. One day a day at the subject's left lower leg test site
About 1 g of the sample was applied to a 5 × 10 cm surface, and the skin condition before the start of the application and three days after the end of the application was visually determined according to the criteria for skin dryness shown in Table 1. The lower leg on the right side was used as a control without applying the sample.
【0032】[0032]
【表1】 [Table 1]
【0033】試験前後の試験部位と対照部位の判定結果
を比較し、皮膚乾燥度が2段階以上改善された場合(例
えば、+→−、++→±)を有効、1段階改善された場
合をやや有効、変化がなかった場合を無効とした。試験
結果は有効、やや有効となった被験者の人数で示した。The test results before and after the test are compared with those of the control site. If the degree of dryness of the skin is improved by two or more stages (for example, + → −, ++ → ±), the case where the skin dryness is improved by one stage is effective. Somewhat valid, no change if no change. The test results were indicated by the number of subjects who were effective or slightly effective.
【0034】(2)角質層改善効果試験 前述の荒れ肌改善効果試験終了後の被験者皮膚にスコッ
チテープ(ニチバンメンディングテープ)を接着し、こ
れを剥離した時テープに付着した角質細胞の状態を走査
型電子顕微鏡によって詳細に調べ、表2の基準によって
皮膚角質細胞抗剥離性を解析し、角質層改善効果(角質
細胞抗剥離性増大効果)を求めた。(2) Stratum corneum improving effect test A scotch tape (Nichiban Mending Tape) is adhered to the subject's skin after the above-mentioned rough skin improving effect test is completed, and when this is peeled off, the state of the keratinous cells adhered to the tape is scanned. The cells were examined in detail by a scanning electron microscope, and the anti-peeling properties of the skin keratinocytes were analyzed according to the criteria shown in Table 2, and the effect of improving the stratum corneum (the effect of increasing the anti-peeling properties of keratinocytes) was determined.
【0035】[0035]
【表2】 [Table 2]
【0036】評価は、4週間連続塗布終了後から3日目
の試験部位の評価点と対照部位のそれとの差が2点以上
の場合を有効、1点の場合をやや有効、0点の場合を無
効とした。試験結果は、20人中有効、やや有効となっ
た被験者の人数で示した。The evaluation is effective when the difference between the evaluation point of the test site and that of the control site on the third day after the end of the continuous application for 4 weeks is 2 or more points, 1 point is slightly effective, and 0 point. Was invalidated. The test results were expressed as the number of subjects who were effective or slightly effective among 20 subjects.
【0037】(3)保湿効果試験(TWL値低減率) 前述の荒れ肌改善効果試験開始前及び終了後の被験者皮
膚を対象とした。4週間連続塗布前及び塗布終了後3日
目にTWL値を測定し、これらの値からTWL値の低減
率(水分保持機能亢進効果)を下記のように算出して、
保湿効果を調べた。(3) Moisturizing Effect Test (TWL Value Reduction Rate) The skin of the subject before and after the start of the above-mentioned rough skin improving effect test was targeted. Before 4 consecutive weeks of application and on the 3rd day after the end of the application, TWL values were measured, and the TWL value reduction rate (water retention function enhancement effect) was calculated from these values as follows.
The moisturizing effect was examined.
【0038】(TWL値の測定法)密閉した皮表上の空
気の一定時間内の湿度変化を電気抵抗に変換して測定す
る方法を用いた。すなわち、被験者の皮表を測定用セル
で密閉し、セルに強制乾燥した空気を通気してセル内を
乾燥空気で充分置換した後、乾燥空気の通気を停止して
その時点でのセル内の相対湿度RHs(%)を求め、次
いで10分間放置して再びセル内の相対湿度RH10
(%)を測定し、この時の湿度変化から下記の式により
TWL値(mg/cm2/hr)を算出した。 TWL値=〔(RH10−RHs)×Dt×V×6〕/
(S×100) 但し、Dt:測定温度下(t℃)での空気中の飽和水蒸
気の密度(mg/l) V :セルの容積(l) S :測定面積(cm2)(Measurement method of TWL value) A method was used in which a change in humidity of air on a closed skin surface within a predetermined time was converted into electric resistance and measured. That is, the skin of the subject is sealed with the measuring cell, forced air is passed through the cell to sufficiently replace the inside of the cell with dry air, and then the ventilation of the dry air is stopped and the inside of the cell at that time is stopped. The relative humidity RHs (%) is obtained, and then left for 10 minutes, and the relative humidity RH10 in the cell is again measured.
(%) Was measured, and a TWL value (mg / cm 2 / hr) was calculated from the change in humidity at this time by the following equation. TWL value = [(RH10−RHs) × Dt × V × 6] /
(S × 100) where Dt: density of saturated water vapor in air at measurement temperature (t ° C.) (mg / l) V: cell volume (l) S: measurement area (cm 2 )
【0039】(TWL値の低減率)TWL値の低減率
は、試料塗布前後のTWL値、TWLA及びTWLBを
下記の式に代入して算出した。 TWL値低減率(%)=(1−TWLB/TWLA)×
100 TWLA:試料塗布前のTWL値 TWLB:試料塗布終了後3日目のTWL値 TWL値の低減率が20%以上の場合を「有効」、低減
率が20%未満の場合を「無効」とした。試験結果は、
20人中の「有効」であった被験者の人数で表示した。(TWL value reduction rate) The TWL value reduction rate was calculated by substituting the TWL values before and after the sample application, TWLA and TWLB into the following equation. TWL value reduction rate (%) = (1−TWLB / TWLA) ×
100 TWLA: TWL value before sample application TWLB: TWL value on the third day after sample application is completed “valid” when the reduction rate of TWL value is 20% or more, and “invalid” when the reduction rate is less than 20% did. The test results are
The number is indicated by the number of subjects who were “effective” out of 20 subjects.
【0040】(4)実用テスト(使用感) 前述の荒れ肌改善効果試験の、終了後3日目の効果を評
価した。試験結果は、皮膚の湿潤性、平滑性、弾力性の
各項目に対して、「皮膚に潤いが生じた」、「皮膚が滑
らかになった」、「皮膚に張りが生じた」と回答した人
数で示した。(4) Practical Test (Feeling of Use) The effect of the above-mentioned rough skin improvement effect test on the third day after completion was evaluated. In the test results, for each item of skin wettability, smoothness, and elasticity, the respondents answered that "skin was moistened", "skin became smooth", and "skin became taut" Indicated by the number of people.
【0041】実施例1〜8、比較例1〜8(スキンクリ
ーム) 表3の組成で、各スキンクリームを調製し、試料とし
た。Examples 1 to 8 and Comparative Examples 1 to 8 (Skin Cream) Each skin cream having the composition shown in Table 3 was prepared and used as a sample.
【0042】(1)組成(1) Composition
【0043】[0043]
【表3】 [Table 3]
【0044】スキンクリーム中に配合した本発明の成分
を表4,5に示す。Tables 4 and 5 show the ingredients of the present invention incorporated in the skin cream.
【0045】[0045]
【表4】 [Table 4]
【0046】[0046]
【表5】 [Table 5]
【0047】(2)調製法 (C)及び(E)成分を(A)成分中に加え、80℃で
加温溶解した後、予め80℃に加温溶解しておいた
(B)及び(D)成分を加えて混合し、ホモミキサーで
分散した。次いで、撹拌しつつ30℃まで冷却して各ス
キンクリームを調製した。(2) Preparation method The components (C) and (E) were added to the component (A), and dissolved by heating at 80 ° C., and then dissolved in advance by heating to 80 ° C. (B) and (B). D) The components were added, mixed, and dispersed with a homomixer. Next, each skin cream was prepared by cooling to 30 ° C. while stirring.
【0048】(3)特性 実施例1〜8、比較例1〜8のスキンクリームについて
実施した、前記各試験結果を表6に示す。(3) Characteristics Table 6 shows the results of the above-mentioned tests performed on the skin creams of Examples 1 to 8 and Comparative Examples 1 to 8.
【0049】[0049]
【表6】 [Table 6]
【0050】表6から、本発明の実施例1〜8のスキン
クリームは、本発明の必須条件を満たさない比較例1〜
8のスキンクリームと比べて、諸特性の全てに亘って優
れていた。また、各実施例は配合特性においても異常は
認められなかった。なお、実施例4〜8は、実施例1〜
3の構成成分に、更にスフィンゴ脂質類を加えた例であ
るが、その結果、実施例4〜8は各試験項目をうわまっ
ており、スフィンゴ脂質類を加えたことによる相乗効果
が認められる。From Table 6, it can be seen that the skin creams of Examples 1 to 8 of the present invention do not satisfy the essential conditions of the present invention.
Compared to the skin cream of No. 8, all the properties were excellent. In each of the examples, no abnormality was recognized in the compounding characteristics. In addition, Examples 4-8 are Examples 1-8.
In this example, sphingolipids were further added to the component No. 3, and as a result, the test items of Examples 4 to 8 are described, and a synergistic effect due to the addition of sphingolipids is recognized.
【0051】実施例9〜14、比較例9〜14(美容
液) 表7の組成で、各美容液を調製し、試料とした。Examples 9 to 14 and Comparative Examples 9 to 14 (Essences) Each of the compositions shown in Table 7 was prepared and used as a sample.
【0052】(1)組成(1) Composition
【0053】[0053]
【表7】 [Table 7]
【0054】美容液中に配合した本発明の成分を表8,
9に示す。Table 8 shows the components of the present invention mixed in the serum.
It is shown in FIG.
【0055】[0055]
【表8】 [Table 8]
【0056】[0056]
【表9】 [Table 9]
【0057】(2) 調製法 (C)及び(E)成分を(A)成分中に加え、80℃で
加温溶解した後、予め80℃に加温溶解しておいた
(B)及び(D)成分を加えて混合し、ホモミキサーで
分散した。次いで、撹拌しつつ30℃まで冷却して各美
容液を調製した。(2) Preparation method Components (C) and (E) were added to component (A), and dissolved by heating at 80 ° C., and then dissolved by heating at 80 ° C. in advance (B) and (B). D) The components were added, mixed, and dispersed with a homomixer. Next, each essence was prepared by cooling to 30 ° C. while stirring.
【0058】(3) 特性 実施例9〜14、比較例9〜14の美容液について実施
した、前記各試験結果を表10に示す。(3) Characteristics Table 10 shows the results of the above-mentioned tests performed on the essences of Examples 9 to 14 and Comparative Examples 9 to 14.
【0059】[0059]
【表10】 [Table 10]
【0060】比較例9〜14の本発明の必須条件を満た
さない美容液に比較して、実施例9〜14の本発明の美
容液は諸試験の全てに亘って良好なる結果が認められ
た。また、各実施例は配合特性においても異常は認めら
れなかった。なお、実施例12〜14は、実施例9〜1
1の構成成分に、更にスフィンゴ脂質類を加えた例であ
るが、その結果、実施例12〜14は各試験項目をうわ
まっており、スフィンゴ脂質類を加えたことによる相乗
効果が認められる。In comparison with the essences of Comparative Examples 9 to 14 which did not satisfy the essential conditions of the present invention, the essences of the present invention of Examples 9 to 14 showed good results over all of the tests. . In each of the examples, no abnormality was recognized in the compounding characteristics. Examples 12 to 14 correspond to examples 9-1.
This is an example in which sphingolipids are further added to the constituent component 1. As a result, Examples 12 to 14 show the test items, and a synergistic effect due to the addition of sphingolipids is recognized.
【0061】実施例15、比較例15(浴用剤) 実施例15の浴用剤組成物を常法により調製し、150
リットルの温湯に浴用剤組成物を20g入れた。20名
のパネラーで、入浴後12時間後の「肌のしっとり感」
・「肌の滑らか感」を、同様に調製した比較例13の浴
用剤組成物との比較により試験を行った。表11に、実
施例15及び比較例15の組成を、また、一対比較評価
法により「効果がある」、あるいは、「良好」と答えた
被験者の人数をそれぞれ示す。Example 15, Comparative Example 15 (Bath agent) The bath agent composition of Example 15 was prepared by a conventional method, and
20 g of the bath composition was placed in 1 liter of hot water. "Moist skin" 12 hours after bathing with 20 panelists
-"Smooth skin feeling" was tested by comparison with the bath preparation composition of Comparative Example 13 similarly prepared. Table 11 shows the compositions of Example 15 and Comparative Example 15 and the number of subjects who answered "effective" or "good" by the paired comparative evaluation method, respectively.
【0062】[0062]
【表11】 [Table 11]
【0063】表11から、実施例15の浴用剤は、本発
明の必須条件を満たさない比較例15の浴用剤と比較し
て、諸試験の全てに亘って良好なる結果が認められた。
また、各実施例は配合特性においても異常は認められな
かった。From Table 11, it was found that the bath preparation of Example 15 had better results over all the tests than the bath preparation of Comparative Example 15 which did not satisfy the essential conditions of the present invention.
In each of the examples, no abnormality was recognized in the compounding characteristics.
【0064】[0064]
【発明の効果】以上記載のように、本発明の皮膚化粧料
は、皮膚の水分保持機能を持続的に亢進、維持する効果
が高く、相乗効果により荒れ肌の改善効果を持ち、使用
感にも優れた皮膚化粧料を提供することは明らかであ
る。As described above, the skin cosmetic of the present invention has a high effect of continuously increasing and maintaining the moisture retention function of the skin, has a synergistic effect of improving rough skin, and has a feeling of use. Clearly, it provides an excellent skin cosmetic.
─────────────────────────────────────────────────────
────────────────────────────────────────────────── ───
【手続補正書】[Procedure amendment]
【提出日】平成9年10月20日[Submission date] October 20, 1997
【手続補正1】[Procedure amendment 1]
【補正対象書類名】明細書[Document name to be amended] Statement
【補正対象項目名】0016[Correction target item name] 0016
【補正方法】変更[Correction method] Change
【補正内容】[Correction contents]
【0016】本発明に用いる、分岐脂肪酸コレステロー
ルエステルはイソ型、アンテイソ型に分離する必要はな
いが、分離して用いても良い。また、これらの分岐脂肪
酸コレステロールエステルは他の脂肪酸コレステロール
エステルとの混合物でも良いが、分岐脂肪酸コレステロ
ールエステルのみからなるものでも良い。これらのイソ
型脂肪酸及びアンテイソ型脂肪酸の総炭素数は融点が低
く、液晶構造を形成する範囲である、10〜37であ
り、好ましくは総炭素数12〜28である。The branched fatty acid cholesterol ester used in the present invention does not need to be separated into an iso form and an ante iso form, but may be used separately. These branched fatty acid cholesterol ester may be a mixture with other fatty acid cholesterol ester, or may consist solely of branched fatty acid cholesterol ester. The total number of carbon atoms of these iso-type fatty acids and anteiso-type fatty acids has a low melting point and is in a range for forming a liquid crystal structure, and is 10 to 37 , preferably 12 to 28 in total.
───────────────────────────────────────────────────── フロントページの続き (72)発明者 三村 邦雄 神奈川県小田原市寿町5丁目3番28号 鐘 紡株式会社化粧品研究所内 ──────────────────────────────────────────────────続 き Continuing on the front page (72) Kunio Mimura 5-28, Kotobukicho, Odawara City, Kanagawa Prefecture Kanebo Co., Ltd.
Claims (2)
脂肪酸のコレステロールエステル及び/又は一般式
(2) 【化2】 (但し、nは6〜32で示される。)で表されるアンテ
イソ型脂肪酸のコレステロールエステル、並びに尿素を
必須成分として含有することを特徴とする皮膚化粧料。1. A compound of the general formula (1) (Where n is 6 to 32) cholesterol ester of iso-fatty acid and / or general formula (2) (Where n is 6 to 32) A skin cosmetic comprising cholesterol esters of anteiso-type fatty acids represented by the formula: and urea as essential components.
を特徴とする請求項1記載の皮膚化粧料。2. The skin cosmetic according to claim 1, further comprising sphingolipids.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21752897A JPH1160432A (en) | 1997-08-12 | 1997-08-12 | Skin cosmetic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP21752897A JPH1160432A (en) | 1997-08-12 | 1997-08-12 | Skin cosmetic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPH1160432A true JPH1160432A (en) | 1999-03-02 |
Family
ID=16705667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP21752897A Pending JPH1160432A (en) | 1997-08-12 | 1997-08-12 | Skin cosmetic |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPH1160432A (en) |
-
1997
- 1997-08-12 JP JP21752897A patent/JPH1160432A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP3112436B2 (en) | In particular, the use of honey as a keratolytic agent to improve the brightness of the skin facial and treat wrinkles | |
| JP6313961B2 (en) | Oil-in-water emulsion composition | |
| JP3383496B2 (en) | Method for producing liquid crystal emulsion and liquid crystal emulsion composition obtained by the method | |
| US20100173027A1 (en) | O/w emulsion for hand care | |
| JPS61271205A (en) | Skin cosmetic | |
| US6066326A (en) | Use of a polydimethylsiloxane containing glucoside groups as a moisturizing agent in a cosmetic or dermatological composition | |
| PT1342473E (en) | Topical application of vitamin e esters | |
| JP2572730B2 (en) | Skin cosmetics | |
| JPH09315931A (en) | Cosmetic material for skin | |
| JP2511820B2 (en) | Skin cosmetics | |
| JPH10175843A (en) | Cosmetic for skin | |
| KR100263623B1 (en) | Cosmetic composition | |
| JPH01207220A (en) | Composition for skin | |
| JP4046426B2 (en) | Ceramide derivative and skin cosmetic containing the same | |
| JPS6281307A (en) | Skin cosmetic | |
| DE102005023636A1 (en) | Active ingredient combinations of glucosylglycerides and creatine and / or creatinine | |
| JP3666083B2 (en) | Skin cosmetics | |
| JPH1160461A (en) | Skin cosmetic | |
| JP2016199567A (en) | Use of alkyl oxazolidinones as moisturizing cosmetics and skin moisturizing methods | |
| KR100521787B1 (en) | Composition for enhancing skin or hair | |
| JPH06271446A (en) | Wrinkle improver | |
| JPH07187982A (en) | Application of cosmetics composition | |
| CN110496065A (en) | Moisturizing composition | |
| JPH11292751A (en) | Skin cosmetic | |
| KR100364314B1 (en) | Use of unfermented honey as a depigmenting agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20040120 |